Study for efficacy and safety of Jie-Xing-Jun-Zi granules in the Treatment of convalescent patients of novel coronavious pneumonia (COVID-19)

Phase 1

• Conditions: ovel Coronavirus Pneumonia (COVID-19)

• Registration Number: ITMCTR2000003243
• Lead Sponsor: Beijing University of Chinese Medicine Third Affiliated Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

(1) Convalescent patients with novel coronavious pneumonia,and the patient is aged 18-75 years old;
(2) The TCM syndrome type conforms to deficiency of 'qi' and 'yin' and not exhausted of 'Yu Xie';
(3) Voluntary test, or the immediate family or the client's approved client agrees to the test, and voluntarily signs the informed consent;
(4) Provide detailed contact information, no short-term willingness to move and be willing to cooperate with followers.

Exclusion Criteria

(1) Patients with fasting water due to gastrointestinal bleeding, intestinal obstruction, etc;
(2) Patients with pre-existing severe brain, heart, liver, kidney and hematopoietic system diseases;
(3) Patients who are known to be allergic to the ingredients of the intervention drug;
(4) Patients who are unable to cooperate with follow-up.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
TCM syndrome curative effect;

Secondary Outcome Measures

Name	Time	Method
Chest CT examination;Lung function;Quality of Life;6MWD;Reversion rate of viral nucleic acid;